VanEck Junior Gold Miners vs Tilray Brands Inc — how do they compare? VanEck Junior Gold Miners trades at $114.41 (market cap $8.22B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: VanEck Junior Gold Miners is far larger — about 15.5× Tilray Brands Inc's market cap, and VanEck Junior Gold Miners is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Tilray Brands Inc for 31 Days on average.
| GDXJ | TLRY | |
|---|---|---|
Market Cap | $8.22B | $530.54M |
Volume | 3,212,198 | 9,099,075 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $21.00 |
52-Week Low | $87.56 | $3.57 |
Typical Hold Time | 41 Days | 31 Days |
Enterprise Value | — | $684.46M |
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $114.43, up 4.85% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF is undergoing significant rebalancing, with multiple junior mining companies like Sinda Ltd. and Hemlo Mining Corp. being added to the fund as of September 2026, which may impact liquidity and composition. Key financial ratios are not applicable as this is an ETF tracking a basket of stocks.
The outlook is mixed; recent gold price strength above $4,400 (24/7 Wall Street, August 16, 2026) supports miner ETFs, but GDXJ's bearish technicals and institutional selling (Amundi reduced its stake by 50.5% as per Defense World, August 6, 2026) suggest caution. Risks include gold price volatility and the high-risk nature of junior miners. Investment appeal hinges on gold's momentum versus the ETF's technical weakness.
TLRY trades at $3.54, down 4.71% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows negative technical momentum with consecutive earnings misses and widening losses despite revenue growth. Recent financials reveal a net loss of $2.19B for 2025, though analyst consensus maintains a $65.01 price target with 25% buy ratings. Business developments include new product launches and leadership changes under Tilray's expanded beverage portfolio.
Outlook remains challenged by profitability concerns and high debt, but potential cannabis regulatory shifts could catalyze recovery. Investment opportunity hinges on execution improvement and market expansion, while risks include sustained cash burn and competitive pressures in the cannabis sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →